Nucryst

( "Nucryst") today announced that it will be distributing to shareholders an additional supplement (the

BioSpace.com Featured News 2010

"Both the placebo and the drug showed about 35% efficacy," says Marvin Wolff, a senior analyst at Paradigm Capital in Toronto, who has been following Nucryst for nearly a decade.

Nucryst's Nano Silver Lining Josh Wolfe 2006

Even if Nucryst cans NP 32101 altogether, the long-term impact on the company won't justify the market reaction.

Nucryst's Nano Silver Lining Josh Wolfe 2006

In fact, dropping the drug at this point may end up saving Nucryst money in the short-term, a silver lining no pun intended that could hold it over until it recovers fully from the long-term revenue loss.

Nucryst's Nano Silver Lining Josh Wolfe 2006

According to the company, Nucryst has seen encouraging pre-clinical results in studies looking at the efficacy of NP 32101 for treating inflammatory bowel disease, including ulcerative colitis.

Nucryst's Nano Silver Lining Josh Wolfe 2006

"Nucryst is continuing to analyze data from this study so that we can evaluate options for our atopic dermatitis program with a complete understanding of the study results," says President and CEO Scott H. Gillis.

Nucryst's Nano Silver Lining Josh Wolfe 2006

And Nucryst might apply its patented manufacturing process, which breaks the bulk silver down and then builds it back up atom by atom into silver nanocrystals, to other noble metals like gold and platinum for formulations to treat diseases as diverse as arthritis and cancer.

Nucryst's Nano Silver Lining Josh Wolfe 2006

Investors had been pinning their hopes on a drug from Massachusetts-based Nucryst Pharmaceuticals aimed at getting rid of eczema, a form of atopic dermatitis that afflicts more than 15 million Americans and has no known cure.

Nucryst's Nano Silver Lining Josh Wolfe 2006

Nucryst is conducting an in-depth analysis of the clinical trial results, after which it will make a decision about whether to proceed with the development of NP 32101 for atopic dermatitis.

Nucryst's Nano Silver Lining Josh Wolfe 2006

So Nucryst must analyze the test to determine why there was this peculiar result.

Nucryst's Nano Silver Lining Josh Wolfe 2006